MCID: FLL003
MIFTS: 33

Fallopian Tube Endometrioid Adenocarcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Fallopian Tube Endometrioid Adenocarcinoma

MalaCards integrated aliases for Fallopian Tube Endometrioid Adenocarcinoma:

Name: Fallopian Tube Endometrioid Adenocarcinoma 12 15 73
Endometrioid Carcinoma of the Fallopian Tube 12
Fallopian Tube Endometrioid Neoplasm 12
Fallopian Tube Endometrioid Cancer 12
Fallopian Tube Endometrioid Tumor 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5831
NCIt 50 C40111 C6279

Summaries for Fallopian Tube Endometrioid Adenocarcinoma

MalaCards based summary : Fallopian Tube Endometrioid Adenocarcinoma, also known as endometrioid carcinoma of the fallopian tube, is related to meningeal melanocytoma and breast papillomatosis. An important gene associated with Fallopian Tube Endometrioid Adenocarcinoma is MME (Membrane Metalloendopeptidase), and among its related pathways/superpathways are Bladder cancer and Platinum drug resistance. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include endothelial, and related phenotypes are Decreased human papilloma virus 16 (HPV16) pseudovirus infection and homeostasis/metabolism

Related Diseases for Fallopian Tube Endometrioid Adenocarcinoma

Diseases related to Fallopian Tube Endometrioid Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 53)
# Related Disease Score Top Affiliating Genes
1 meningeal melanocytoma 10.5 CDKN2A MME
2 breast papillomatosis 10.4 CDKN2A ERBB2
3 breast benign neoplasm 10.4 ERBB2 MME
4 thoracic benign neoplasm 10.4 ERBB2 MME
5 vulval paget's disease 10.4 CDKN2A ERBB2
6 mixed cell type cancer 10.4 ERBB2 MME
7 vulva adenocarcinoma 10.4 CDKN2A ERBB2
8 oral leukoplakia 10.4 CDKN2A ERBB2
9 cervix endometriosis 10.4 CALB2 MME
10 malignant leydig cell tumor 10.4 CALB2 MME
11 adenofibroma 10.4 CALB2 MME
12 rete testis adenocarcinoma 10.4 CALB2 MME
13 breast papillary carcinoma 10.4 ERBB2 MME
14 ewing's family of tumors 10.4 CDKN2A ERBB2
15 lymphohistiocytoid mesothelioma 10.4 CALB2 CDKN2A
16 acute lymphoblastic leukemia, childhood 10.4 CDKN2A MME
17 mucinous bronchioloalveolar adenocarcinoma 10.4 CALB2 CDKN2A
18 rete testis neoplasm 10.4 CALB2 MME
19 spermatocele 10.3 CALB2 MME
20 cystadenofibroma 10.3 CALB2 MME
21 barrett's adenocarcinoma 10.3 CDKN2A ERBB2
22 breast fibroadenoma 10.3 ERBB2 MME
23 pancreatic mucinous cystadenoma 10.3 CALB2 MME
24 leukemia, acute lymphoblastic 3 10.3 CDKN2A MME
25 bladder squamous cell carcinoma 10.3 CDKN2A ERBB2
26 lung combined type small cell carcinoma 10.3 MME MYOG
27 pleural cancer 10.3 CALB2 CDKN2A
28 in situ carcinoma 10.3 CDKN2A ERBB2
29 ovarian brenner tumor 10.3 CALB2 MME
30 cervical adenocarcinoma 10.2 CDKN2A ERBB2
31 renal cell carcinoma, papillary, 1 10.2 ERBB2 MME
32 endometrial adenocarcinoma 10.2 CDKN2A ERBB2
33 conventional leiomyosarcoma 10.2 CDKN2A MYOG
34 nephrogenic adenofibroma 10.2 MME MYOG
35 uterine carcinosarcoma 10.1 ERBB2 MME
36 respiratory system cancer 10.1 CDKN2A ERBB2
37 liposarcoma 10.1 CALB2 CDKN2A
38 acute lymphocytic leukemia 10.1 CDKN2A MME
39 mesothelioma, malignant 10.1 CALB2 CDKN2A
40 spindle cell liposarcoma 10.1 CALB2 MYOG
41 cell type cancer 10.0 CDKN2A ERBB2
42 early invasive cervical adenocarcinoma 10.0 CDKN2A INSM1
43 cervix uteri carcinoma in situ 10.0 CDKN2A INSM1
44 gastrointestinal system cancer 9.9 CDKN2A ERBB2
45 microinvasive cervical squamous cell carcinoma 9.9 INSM1 PTPRN
46 cholangiocarcinoma 9.9 CDKN2A ERBB2 MME
47 lung cancer susceptibility 3 9.7 CALB2 CDKN2A ERBB2
48 transitional cell carcinoma 9.6 CDKN2A ERBB2
49 pre-malignant neoplasm 9.5 CDKN2A ERBB2 INSM1
50 dysgerminoma of ovary 9.3 CALB2 INSM1 PTPRN

Graphical network of the top 20 diseases related to Fallopian Tube Endometrioid Adenocarcinoma:



Diseases related to Fallopian Tube Endometrioid Adenocarcinoma

Symptoms & Phenotypes for Fallopian Tube Endometrioid Adenocarcinoma

GenomeRNAi Phenotypes related to Fallopian Tube Endometrioid Adenocarcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased human papilloma virus 16 (HPV16) pseudovirus infection GR00306-A 8.92 CALB2 CDKN2A ERBB2 MYOG

MGI Mouse Phenotypes related to Fallopian Tube Endometrioid Adenocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.43 CDKN2A ERBB2 INSM1 MME MYOG PTPRN
2 respiratory system MP:0005388 8.92 CDKN2A ERBB2 INSM1 MYOG

Drugs & Therapeutics for Fallopian Tube Endometrioid Adenocarcinoma

Drugs for Fallopian Tube Endometrioid Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 48)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
4
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 3 23214-92-8 31703
5
Gemcitabine Approved Phase 3 95058-81-4 60750
6
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
7
Olaparib Approved Phase 2, Phase 3 763113-22-0 23725625
8
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
9
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
10
Doxil Approved June 1999 Phase 2, Phase 3,Phase 3 31703
11
Cediranib Investigational Phase 2, Phase 3 288383-20-0 9933475
12
Maleic acid Experimental Phase 2, Phase 3 110-16-7 444266
13 Mitogens Phase 3,Phase 2,Phase 1
14 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
15 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
16 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
17 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
18 Immunoglobulin G Phase 3,Phase 2,Phase 1
19 Antibodies Phase 3,Phase 2,Phase 1
20 Immunoglobulins Phase 3,Phase 2,Phase 1
21 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
22 Antimitotic Agents Phase 3,Phase 2,Phase 1
23 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
24 Micronutrients Phase 3
25 Topoisomerase Inhibitors Phase 2, Phase 3,Phase 3
26 Trace Elements Phase 3
27 Anti-Bacterial Agents Phase 2, Phase 3,Phase 3
28 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 3
29 Immunosuppressive Agents Phase 3,Phase 2
30 Carotenoids Phase 3
31 taxane Phase 3
32 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3,Phase 1
33 Anti-Infective Agents Phase 3
34 Protein Kinase Inhibitors Phase 2, Phase 3
35 Antimetabolites Phase 3
36 Antiviral Agents Phase 3
37 Antimetabolites, Antineoplastic Phase 3
38 topoisomerase I inhibitors Phase 2, Phase 3
39
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
40
Pembrolizumab Approved Phase 2 1374853-91-4
41
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
42 Alkylating Agents Phase 2
43 Antirheumatic Agents Phase 2
44 Antineoplastic Agents, Alkylating Phase 2
45
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
46
Cisplatin Approved Phase 1 15663-27-1 84093 441203 2767
47
Veliparib Investigational Phase 1 912444-00-9 11960529
48 CHI3L1 protein, human

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
3 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
4 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT01167712 Phase 3 Carboplatin;Paclitaxel
5 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
6 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT00565851 Phase 3 Carboplatin;Docetaxel;Gemcitabine Hydrochloride;Paclitaxel
7 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
8 Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02853318 Phase 2 Cyclophosphamide
9 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02713386 Phase 1, Phase 2 Carboplatin;Paclitaxel;Ruxolitinib Phosphate
10 Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting NCT02345265 Phase 2 Cediranib Maleate;Olaparib
11 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
12 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
13 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
14 YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Terminated NCT00899093

Search NIH Clinical Center for Fallopian Tube Endometrioid Adenocarcinoma

Genetic Tests for Fallopian Tube Endometrioid Adenocarcinoma

Anatomical Context for Fallopian Tube Endometrioid Adenocarcinoma

MalaCards organs/tissues related to Fallopian Tube Endometrioid Adenocarcinoma:

41
Endothelial

Publications for Fallopian Tube Endometrioid Adenocarcinoma

Articles related to Fallopian Tube Endometrioid Adenocarcinoma:

# Title Authors Year
1
Endometrioid carcinoma of the fallopian tube resembling an adnexal tumor of probable wolffian origin: a case of report and review of the literature. ( 19457622 )
2010
2
Endometrioid carcinoma of the fallopian tube resembling a female adnexal tumor of probable wolffian origin. ( 15322493 )
2004
3
A case of endometrioid carcinoma of the fallopian tube mimicking an adnexal tumor of probable Wolffian origin. ( 10379682 )
1999

Variations for Fallopian Tube Endometrioid Adenocarcinoma

Expression for Fallopian Tube Endometrioid Adenocarcinoma

Search GEO for disease gene expression data for Fallopian Tube Endometrioid Adenocarcinoma.

Pathways for Fallopian Tube Endometrioid Adenocarcinoma

Pathways related to Fallopian Tube Endometrioid Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.82 CDKN2A ERBB2
2 10.49 CDKN2A ERBB2

GO Terms for Fallopian Tube Endometrioid Adenocarcinoma

Biological processes related to Fallopian Tube Endometrioid Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of transcription, DNA-templated GO:0006355 9.8 CDKN2A ERBB2 INSM1 MYOG PTPRN
2 transcription, DNA-templated GO:0006351 9.72 CDKN2A ERBB2 INSM1 MYOG PTPRN
3 negative regulation of cell proliferation GO:0008285 9.54 CDKN2A INSM1 MYOG
4 cellular response to growth factor stimulus GO:0071363 9.26 ERBB2 MYOG
5 positive regulation of cell cycle arrest GO:0071158 9.16 INSM1 MYOG
6 replicative senescence GO:0090399 8.96 CDKN2A MME
7 negative regulation of immature T cell proliferation in thymus GO:0033088 8.62 CDKN2A ERBB2

Molecular functions related to Fallopian Tube Endometrioid Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 core promoter binding GO:0001047 8.96 INSM1 MYOG
2 chromatin DNA binding GO:0031490 8.62 INSM1 MYOG

Sources for Fallopian Tube Endometrioid Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....